Puma Biotechnology (0PB) Financial Statements
Puma Biotechnology Financial Overview
Puma Biotechnology's market cap is currently $482.54M. The company's EPS TTM is $0.54; its P/E ratio is 19.47; Puma Biotechnology is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $0.08. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 228.37M | $ 230.47M | $ 235.64M | $ 228.03M | $ 253.16M |
| Gross Profit | $ 170.21M | $ 166.06M | $ 172.96M | $ 172.94M | $ 189.45M |
| Operating Income | $ 37.30M | $ 30.97M | $ 32.64M | $ 23.72M | $ 1.29M |
| EBITDA | $ 53.34M | $ 48.08M | $ 47.52M | $ 21.89M | $ -4.69M |
| Net Income | $ 31.11M | $ 30.28M | $ 21.59M | $ 2.00K | $ -29.13M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 97.53M | $ 100.97M | $ 95.94M | $ 81.07M | $ 82.11M |
| Total Assets | $ 216.30M | $ 213.33M | $ 230.53M | $ 222.06M | $ 226.59M |
| Total Debt | $ 28.55M | $ 74.08M | $ 111.49M | $ 114.28M | $ 116.64M |
| Net Debt | $ -1.09M | $ 4.86M | $ 26.91M | $ 38.08M | $ 53.51M |
| Total Liabilities | $ 85.96M | $ 121.21M | $ 177.09M | $ 200.45M | $ 229.03M |
| Stockholders' Equity | $ 130.34M | $ 92.13M | $ 53.44M | $ 21.61M | $ -2.45M |
| Cash Flow | |||||
| Free Cash Flow | $ 41.73M | $ 38.86M | $ 14.37M | $ -22.83M | $ 20.65M |
| Operating Cash Flow | $ 41.80M | $ 38.92M | $ 27.01M | $ -15.83M | $ 20.65M |
| Investing Cash Flow | $ -36.19M | $ -20.44M | $ -19.13M | $ 7.10M | $ -10.88M |
| Financing Cash Flow | $ -45.20M | $ -33.85M | $ 0.00 | $ 12.22M | $ -31.93M |
Currency in USD
